Orphan Drugs In Development For The Treatment Of Friedreich's Ataxia: Focus On Omaveloxolone.
Ontology highlight
ABSTRACT: Friedreich's Ataxia (FRDA) is a devastating and progressive ataxia, marked by mitochondrial dysfunction and oxidative stress. Nrf2 activators such as omaveloxolone (Omav) modulate antioxidative mechanisms, and thus may be viable therapeutic agents in FRDA.
SUBMITTER: Ghanekar SD
PROVIDER: S-EPMC6800542 | biostudies-literature | 2019
REPOSITORIES: biostudies-literature
ACCESS DATA